VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas

European Journal of Haematology

Volumn 61, Issue 4, 1998, Pages 261-265

  Yalçin, Şuayib ^a   Kars, Ayşe ^a   Ozişik, Yavuz ^a   Tekuzman, Gülten ^a   Özyilkan, Özgür ^a   Çelik, Ismail ^a   Barişta, Ibrahim ^a   Güllü, Ibrahim ^a   Güler, Nilüfer ^a   Baltali, Eşmen ^a   Firat, Dinçer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Aggressive; Combination chemotherapy; Non Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPATHY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

EID: 7844232933     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01712.x     Document Type: Article

References (20)

1. SHIPP MA, MAUCH PM, HARRIS NL. Non-Hodgkin's lymphomas In: DEVITA VT Jr, HELMANN S, ROSENBERG SA, ed. Cancer Principles and Practice of Oncology. Philadelphia. JB Lippincott 1997: 2165-2220.
2. FISHER RI. Treatment of agressive non-Hodgkin's lymphomas, lessons from the past 10 years. Cancer suppl 1994: 74: 2657-2661.
3. CABANILLAS F. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience. Semin Oncol 1992: 19(suppl 1): 11-13.
4. DEVITA VT JR, CANELLOS GP, CHABNER BA, et al. Advanced diffuse histiocytic lymphoma. A potentially curable disease. Lancet 1975: 1: 248-250.
5. MCKELVEY EM, GOTTLIEB JA, WILSON HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976: 38: 1484-1493.
6. KLIMO P, CONNORS JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985: 102: 596-602.
7. SAKARIN AT, ROSENTHAL DS, MOLONEY WC, et al. Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP). Blood 1977: 49: 759-770.
8. COIFFER B, GISSELBRECHT C, HERBRECHT R, et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989: 7: 1018-1026.
9. ARMITAGE JO, CHESON BD. Interpretation of clinical trials in diffuse large cell lymphoma. J Clin Oncol 1988: 6: 1335-1347.
10. DANA BW, DAHLBERG S, MILLER TP, et al. m-BACOD treatment for intermediate-and high-grade malignant lymphomas: a Southwest Oncology group Phase II trial. J Clin Oncol 1990: 8: 1155-1162.
11. WEICK JK, DAHLBERG S, FISHER RI, et al. Combination chemotherapy of intermediate-grade and high grade non Hodgkin's lymphoma with MACOP-B: a southwest Oncology Group study. J Clin Oncol 1991: 9: 748-753.
12. FISHER RI, GAYNOR ER, DAHLBERG S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993: 328: 1002-1006.
13. FISHER RI, GAYNOR ER, DAHLBERG S, et al. A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytoBOM vs MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the national High-Priority lymphoma study. Ann Oncol 1994: 5 (suppl 2): 91-95.
14. GORDON LI, HARRINGTON D, ANDERSEN J, et al. Comparison of a second generation combination chemotherapeudic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992: 327: 1342-1349.
15. ARMITAGE JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993: 328: 1023-1030.
16. JONES SE, FUKS Z, KAPLAN HS, et al. Non-Hodgkin's lymphoma V. Results of radiotherapy. Cancer 1973: 32: 682-691.
17. COLTMAN CA, LUCE JK, MCKELVEY EM, et al. Chemotherapy of non-Hodgkin's lymphoma: ten years experience in the southwest Oncology Group. Cancer Treat Rep 1977: 61: 1067-1078.
18. BLUM RH, CARTER SK. Adriamycin. A new anti cancer drug with significant clinical activity. Ann Intern Med 1974: 80: 249-259.
19. GOLDIE JH, COLDMAN AJ, GUDAUSKAS GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982: 66: 439-449.
20. ÖZIŞIK Y, KARS A, BARIŞTA I, et al. The role of bleomycin, cyclophosphamide, mitoxantrone, vinristine and prednisone (BCNOP) regimen in non-Hodgkin's lymphoma. Turk J Cancer 1994: 24: 20-27.